DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Trastuzumab emtansine
Trastuzumab emtansine
Press Release
07052020 MR ASCO20 Curtain Raiser
Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy
Trastuzumab and Paclitaxel in Patients with EGFR Mutated NSCLC That Express HER2 After Progression on EGFR TKI Treatment
Changing the Destiny of HER2 Expressing Solid Tumors
Trastuzumab Emtansine (T-DM1)
Trastuzumab Emtansine: a Novel Antibody-Drug Conjugate for HER2-Positive Breast Cancer
Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma
Abnormal Corneal Lesions Induced by Trastuzumab Emtansine: an Antibody–Drug Conjugate for Breast Cancer
EML) and Model List of Essential Medicines for Children (Emlc
For Health Professionals Who Care for Cancer Patients
HER2-Targeted Immunotherapy and Combined Protocols Showed Promising Antiproliferative Effects in Feline Mammary Carcinoma Cell-Based Models
For Health Professionals Who Care for Cancer Patients
Five Years of Cancer Drug Approvals
Expanding Frontiers, Transforming Cancer Treatment
125427Orig1s000
Kinase Drug Discovery 20 Years After Imatinib: Progress and Future Directions
(Trastuzumab-DM1) for Treatment of HER-2 Positive Malignancies
Top View
Factors Affecting the Pharmacology of Antibody–Drug Conjugates
Ado-Trastuzumab Emtansine (Kadcyla®) Prior Authorization Drug Coverage Policy
NCCN Guidelines for Central Nervous System Cancers Cancer V.1.2021 – Annual 10/23/2020
"Use of This Document Is Governed by the Terms of Use on the First Page of This Document." # Section Comments 2020
NCCN Guidelines for Patients Metastatic Breast Cancer
125427Orig1s000
Solving the Puzzle of Treatment Resistance in Patients with HER2-Positive Metastatic Breast Cancer – New Approaches to HER Target Family Network
2019 Table of Drugs
Trastuzumab Emtansine Is Active on HER-2 Overexpressing NSCLC Cell
Molecular Targeting of HER2-Overexpressing Biliary Tract Cancer Cells with Trastuzumab Emtansine, an Antibody–Cytotoxic Drug Conjugate
Real-World Effectiveness of Post-Trastuzumab Emtansine
Strategic Collaboration in Oncology Trastuzumab Deruxtecan (DS-8201)
Trastuzumab Deruxtecan
Ado-Trastuzumab Emtansine (KADCYLA) Drug Monograph
Kadcyla® (Ado-Trastuzumab Emtansine)
Drug Information Center Highlights of FDA Activities – 4/1/2020
DRUG NAME: Trastuzumab Emtansine
Enhertu (Trastuzumab Deruxtecan)
March 2015 Medicaid Bulletin
Oncofocus Patient Test Report
(T-DM1) in HER2-Positive Breast Cancer
Foundationone Cdx Sample Report
Fam-Trastuzumab Deruxtecan-Nxki (Enhertu®)
List of Cleared Or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)
Ado-Trastuzumab Emtansine I Chemotherapy: Ado-Trastuzumab Emtansine (Kadcyla®) Pronounced: “A-Do-Tras-TU-Zoo-Mab Em-TAN-Seen”
The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer
KADCYLA (Ado-Trastuzumab Emtansine) and Not Trastuzumab
The Obesity Paradox in Early and Advanced HER2 Positive Breast Cancer: Pooled Analysis of Clinical Trial Data ✉ Natansh D
Is a Potential Therapeutic Target in Extramammary Paget's Disease Of
KADCYLA (Ado-Trastuzumab Emtansine) Label
Clinical Trials Appendix Q1 2019 Results Update
Clinical Trials Appendix Q1 2021 Results Update
Phase 1B Clinical Trial of Ado-Trastuzumab Emtansine and Ribociclib for HER2-Positive Metastatic Breast Cancer
Treatment and Side Effects
Emtansine (T-DM1) Resistance in HER2-Positive Cancer
Design and Implementation of an Intelligent Framework for Supporting Evidence-Based Treatment Recommendations in Precision Oncology
Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2
In HER2-Positive Breast Cancer Cells
Efficacy of Combination Treatment Modalities for Intermediate and Advanced Hepatocellular Carcinoma: Intra-Arterial Therapies, Sorafenib and Novel Small Molecules
(T-DM1) in HER2 Positive Breast Cancer
Kadcyla (Trastuzumab Emtansine) and Notanother Trastuzumab-Containing Product (E.G
The Tale of HER2